Video & Transcript Research : 'drug development'

Page 1 of 500
AZ

Arizona 2026 Regular Session

02/18/2026 - House International Trade

International Trade

Transcript Highlights:
  • In bulk drug substances.
  • compounded under the Federal Food, Drug, and Cosmetic Act using a drug substance that is a receptor
  • compounded under the Federal Food, Drug, and Cosmetic Act using a drug substance that is a receptor
  • They're not approved as a drug.
  • or an FDA-approved drug.
Summary: The committee first heard a presentation from Berthold Barak Karlich of Benor Capital on investment, innovation, and trade from a European perspective. He argued that legacy is about enabling future generations through open, connected systems rather than isolation, highlighted Austria’s “hidden champion” SMEs and strong education/research base, and said innovation thrives through international collaboration. He also discussed AI and deep tech investment, emphasizing photonic computing and the need to support hardware that enables future AI systems. In response to questions, he said Arizona appears friendly and strong in deep tech and that he will explore opportunities there. The committee then considered HB 2746, which creates a study committee on trade offices under the Arizona Commerce Authority to review existing trade offices, gather stakeholder input, and make recommendations. Members discussed oversight of Arizona’s trade offices in several countries and the need to evaluate effectiveness. The bill passed with a due pass recommendation by a 7-0 vote. HB 2750, which establishes the Arizona-Sonora Trade Commission to improve trade, commerce, and tourism ties with Sonora, Mexico, also passed, with some members expressing interest in further discussion about its relationship to the Arizona-Mexico Commission; it received a 5-1-1 recommendation. The committee next took up HB 4036, a bill regulating compounded GLP-1 weight-loss drugs and related bulk drug substances, including restrictions on sale and distribution, testing and sourcing requirements, advertising disclosures, penalties, and pharmacy board inspection authority. Supporters, including representatives from Novo Nordisk and the Partnership for Safe Medicines, argued the bill addresses unsafe imported ingredients, misleading advertising, and a surge in unregulated compounded weight-loss products. Opponents from the Arizona Pharmacy Association, a compounding pharmacist, and a physician said the bill would burden lawful compounders, raise costs, reduce access, and could affect other legitimate compounded medications. After extensive debate, the motion for a due pass recommendation failed on a 5-5 tie. Finally, the committee heard a strike-everything amendment to HB 2765 creating a vapor product manufacturer licensing framework, fees, penalties, and Department of Revenue oversight aimed at stopping smuggled vape products. The sponsor said the measure was intended to target illegal imports and protect children, while opponents from the Vapor Technology Association and Arizona Innovates argued it would burden lawful businesses and that the real problem is illegal actors and targeted enforcement. The discussion continued with questions about federal law, flavored vape products, and whether the bill would affect compliant manufacturers, but the transcript ends before any final vote on HB 2765.
US
Transcript Highlights:
  • They'll help make prescription drugs more affordable.
  • Hopefully, transparency driving down the cost of prescription drugs.
  • The fact is drug prices are too high.
  • The Drug Competition Enforcement Act would prohibit product hopping.
  • drug dealer. manufacturer from offering patients a far more affordable generic version of the drug.
Summary: The meeting focused on addressing the high cost of prescription drugs and the abusive practices that contribute to elevated prices affecting American families. Several bills were presented, including proposals to end pay-for-delay deals and to enhance transparency in the operations of pharmacy benefit managers (PBMs). The discussion was notable for its emphasis on consumer protection and ensuring that cheaper generic drugs reach the market more effectively. Members expressed frustration over past attempts to pass similar legislation stalling in the Senate, leading to renewed efforts to push these bills forward.
OK

Oklahoma 2026 Regular Session

Local and County Government Feb 3rd, 2026 at 01:30 pm

Local and County Government

Transcript Highlights:
  • Senate Bill 1775 clarifies that for any traffic, alcohol, or drug-related offenses with a penalty established
  • not listed in state law at $200 for traffic-related offenses, $800 for alcohol-related offenses, and drug-related
  • It allows a municipality to find or develop a proposal for a penalty equal to the state statute.
  • I am was I'm just reading about alcohol-related or drug-related penalties.
US
Transcript Highlights:
  • Americans to drug poisonings, primarily due to illicit fentanyl flooding across our borders.
  • They're involved in drugs, fentanyl. Extortion, kidnapping, drugs, intimidation, money laundering.
  • I'm claiming that... ...in terms of drug dealing? Sorry to interrupt you, sir.
  • How does this diversion of resources help us fight drugs in our communities?
  • And so many times violent crime is tied to drug trafficking.
Summary: The committee meeting centered on the urgent crisis of fentanyl abuse and the government’s response to the drug trafficking epidemic. Key discussions revolved around the nomination of Terrence Cole as the Administrator of the DEA and Judea Serrata as Director of the U.S. Marshals Service. Cole emphasized his commitment to combating the fentanyl crisis, highlighting the rising number of overdose deaths and the necessity of bipartisan efforts to dismantle drug cartels. Members engaged in dialogue on the effectiveness of various strategies and the importance of education aimed at preventing drug-related deaths among youth. Additionally, the challenges of social media in drug trafficking were highlighted, indicating a need for greater accountability in how platforms handle such issues. Senators voiced concerns about the impact of administration policies on judicial security and the resources available for marshals to perform their critical roles.
OK

Oklahoma 2026 Regular Session

Appropriations Revised Apr 22nd, 2026 at 03:30 pm

Appropriations

Transcript Highlights:
  • Recently, President Trump has released some executive orders around research on this drug.
  • In doing so, he learned that the drug screening panels used in the child welfare process did not test
  • for fentanyl, which is not detected by standard drug panels.
  • back home, they, like me, were shocked that fentanyl was not already included in the child welfare drug
  • require the Oklahoma Department of Human Services to include fentanyl testing in all child welfare drug
US
Transcript Highlights:
  • It's the deadliest drug in American history.
  • It's actually used by people who are using drugs to test their drug beforehand.
  • To see, am I really taking an Adderall or whatever the drug that again is illegal.
  • Chairman, of wanting to defer to states, but in the area of drug enforcement and drug definition and
  • drug scheduling, that really is very much a federal function.
Bills: SB331
Summary: In this committee meeting, the focus was primarily on S-331, the Halt All Lethal Trafficking and Fentanyl Act, aimed at addressing the fentanyl crisis. The bill's key components include making permanent the class scheduling of fentanyl-related substances, confirming existing sentencing penalties, and easing registration requirements for scientific research on Schedule I substances. Numerous parents shared heartbreaking testimonies about their losses due to fentanyl, which fueled an urgent call to pass the legislation without alterations. The committee members engaged in passionate discussions highlighting the urgency of the situation as overdoses continue to claim American lives.
OK

Oklahoma 2026 Regular Session

Senate Legislative Session Apr 15th, 2026 at 01:30 pm

Oklahoma Senate Floor Meeting

Transcript Highlights:
  • entire state by promoting learning, advancing knowledge, enriching lives, and stimulating economic development
  • reputation as one of college football's most innovative offensive minds and a proven leader dedicated to developing
  • career, Coach Morris has built some of the nation's most dynamic offenses and has helped recruit and develop
  • continue Oklahoma State University's proud tradition of competitive success and strong character development
  • These donations are to be utilized in purchasing equipment, developing capital projects, acquiring properties
WY

Wyoming 2026 Regular Session

House Judiciary Committee, February 23, 2026

Judiciary

Transcript Highlights:
  • distributing methamphetamine or controlled substance and scheduled one or two, which is a narcotic drug
  • is a narcotic drug for a person<00:02:21.280> under<00:02:21.680> 18<00:02:22.160>
  • ...other drugs, you know, it's being combined with other drugs.
  • to, how do we prove that the person who sold the drug knew that there was a fentanyl mixture?
  • He may be in court right now drug cases.
Bills: SF0009
MN

Minnesota 2025-2026 Regular Session

House Health Finance and Policy Committee 3/9/26

Health Finance and Policy

Transcript Highlights:
  • The organization must keep records even for drugs that it does not accept.
  • The organization must keep records even for drugs that it does not accept this.
  • That pain led me straight to alcohol and hard drugs. By the time I was 17, I was lost.
  • Let me straighten alcohol and hard drugs.
  • It's not about drugs; it's about medicine.
MS

Mississippi 2026 Regular Session

Drug Policy - Room 409, 26 February, 2026; 2:30 P.M.

Drug Policy

Transcript Highlights:
  • We will now call the meeting of the Senate Drug Policy Committee to order.
  • So, so these are all Schedule One drugs? >> Correct.
  • Senator Fillingane. >> Drug would be available for?
  • And so, like these other drugs, they will simply be listed, and those providers could choose based on
  • And so, like these other drugs, they will simply be listed, and those providers could choose based on
Summary: The Senate Drug Policy Committee met to consider two bills. For House Bill 417, which updates the Uniform Controlled Substances Act by adding substances to Schedule I, committee counsel explained that a strike-all was needed because the House version relied on outdated correspondence. Anna Catherine Lambert of the Mississippi State Department of Health said the department updates the language each year by matching Mississippi law to the DEA’s Federal Register, including salts, isomers, and related forms of newly scheduled substances. She noted the additions largely fall into three broad categories, including fentanyl derivatives, phenidates, and tazenes. Senators asked about the number of compounds and the need to list each derivative form. The committee moved to adopt the strike-all and then the title sufficient do pass strike-all, and the bill was reported. The committee then took up House Bill 563, which would allow Mississippi law to conform automatically if psilocybin is scheduled by the federal government before the next legislative session. The chair described psilocybin as a mushroom-derived compound being studied in clinical trials for treatment-resistant depression, and noted that an email from Veterans Exploring Treatment Options supported the legislation. Members discussed that the bill would prevent delay if federal scheduling occurs and asked about the conditions for which the substance might be used; the response mentioned treatment-resistant depression, traumatic brain injury, substance use disorder, and other mental health indications. Senator Blackmon made a lighthearted comment about possible amendments, but no amendments were adopted. The committee approved the motion for title sufficient to pass, and House Bill 563 was reported.
US
Transcript Highlights:
  • Moving on to the Food and Drug Administration, they've confirmed, as FDA Commissioner Dr.
  • We have made progress under the Biden administration in terms of negotiating prescription drug prices
  • into new prescription drugs that have provided enormous benefits.
  • Unfortunately, despite all of the money that we We have spent on the development of prescription drugs
  • Drug companies take the money.
Summary: The meeting focused on vital health-related nominations, primarily emphasizing the roles of Dr. Jay Bhattacharya for NIH Director and Dr. Monty McCary for FDA Commissioner. During the discussion, various senators expressed their support and concerns regarding these nominations. Senator Sanders voiced opposition to both candidates, highlighting issues related to drug affordability and public trust in health agencies. He emphasized the need for leaders committed to transparency and addressing the epidemic of high prescription drug prices, advocating for action against pharmaceutical industry greed. Overall, the conversation underscored the critical crossroads in public health leadership amidst ongoing challenges such as trust restoration and healthcare accessibility.